These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11862010)

  • 1. Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
    Yazaki H; Kikuchi Y; Oka S
    Jpn J Infect Dis; 2001 Dec; 54(6):246-7. PubMed ID: 11862010
    [No Abstract]   [Full Text] [Related]  

  • 2. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 3. An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice.
    Elion R; Green L; Cohen C; Green S; Baird I; Schrader S; Ward D
    Antivir Ther; 1999; 4 Suppl 3():89-91. PubMed ID: 16021878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 5. Photosensitive drug eruption induced by efavirenz in a patient with HIV infection.
    Furue M
    Intern Med; 2004 Jul; 43(7):533. PubMed ID: 15335175
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral chemotherapy.
    Saag MS; Schooley RT
    Curr Clin Top Infect Dis; 1998; 18():154-79. PubMed ID: 9779354
    [No Abstract]   [Full Text] [Related]  

  • 8. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelomeningocele in a child with intrauterine exposure to efavirenz.
    Fundarò C; Genovese O; Rendeli C; Tamburrini E; Salvaggio E
    AIDS; 2002 Jan; 16(2):299-300. PubMed ID: 11807320
    [No Abstract]   [Full Text] [Related]  

  • 10. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz decreases methadone blood concentrations.
    Marzolini C; Troillet N; Telenti A; Baumann P; Decosterd LA; Eap CB
    AIDS; 2000 Jun; 14(9):1291-2. PubMed ID: 10894303
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
    van Leth F; Hall DB; Lange JM; Reiss P
    HIV Med; 2006 Sep; 7(6):347-50. PubMed ID: 16903977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-ranging studies.
    Manion D
    Int J Clin Pract Suppl; 1999 Jun; 103():8-9. PubMed ID: 10622036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
    Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK;
    J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz-induced leukocytoclastic vasculitis.
    Domingo P; Barceló M
    Arch Intern Med; 2002 Feb; 162(3):355-6. PubMed ID: 11822931
    [No Abstract]   [Full Text] [Related]  

  • 17. [Progress in HIV therapy. Effective and simple therapy with efavirenz].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():36-7. PubMed ID: 11373774
    [No Abstract]   [Full Text] [Related]  

  • 18. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
    Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
    Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.